trabecular separation of MK3 deficient, MK2 deficient and MK2/3 deficient mice compared with wild type. MK3 deficient bones have lower trabecular number and higher trabecular separation than MK2 deficient bone while MK2/3 deficient bones showed the same phenotype than MK2 deficient bones. Number of osteoclasts was reduced in MK3 deficient, MK2 deficient and MK2/3 deficient bones in vivo compared with wild type. Number of osteoclasts was higher in MK3 deficient bones than in MK2 bones, MK2/3 deficient bones showed the same number of osteoclasts than MK2 deficient bones. Ex vivo osteoclast differentiation assay showed reduced osteoclasts number using MK3, MK2 and MK2/3 deficient cells compared with wild type cells.

Conclusions MK3 deficient mice showed increased trabecular bone volume than wild type mice, but trabecular volume was less increased than in MK2 deficient mice. MK2/3 deficient mice showed no additional effect compared to MK2 deficient mice. Increased trabecular volume was associated with reduced number of osteoclasts due to impaired osteoclast differentiation. Thus MK3 regulated osteoclast differentiation and bone homeostasis but there is no additional effect to MK2.

### A8.11 RANKL Expression is Lower on T and B lymphocytes and RANKL Cells Tend to Accumulate in Circulation of Rheumatoid Arthritis Patients Treated with TNF Blockers

doi:10.1136/annrheumdis-2013-203222.11

1IP Perpétuo, 2R Marques, 3C Ponte, 1H Canhão, 2JE Fonseca. Rheumatology Research Unit, Instituto de Medicina Molecular da Faculdade de Medicina da Universidade de Lisboa, Portugal; 2Lisbon Academic Medical Centre, Portugal

**Background and Objectives** Rheumatoid arthritis (RA) is characterised by bone resorption and joint destruction. The receptor activator of NF-kB ligand (RANKL) plays a major role in bone loss because it is responsible for osteoclast differentiation and it is known that hyperactive immune system cells express surface RANKL. Several therapies commonly used for RA treatment have been shown to stop RANKL expression on T and B lymphocytes (p = 0.0003 and p = 0.0070 and p = 0.0183 respectively). No differences were found between groups regarding circulating number of leukocytes. We found no correlation of the studied parameters with CRP, ESR or DAS28.

**Patients** Patients treated with MTX or TNF blockers have reduced RANKL expression in neutrophils, T and B lymphocytes (p = 0.0027, p = 0.0003 and p = 0.0032, respectively) when compared to untreated patients. However the number of circulating RANKL+ T and B lymphocytes was increased in patients treated with TNF blockers when compared to naïve patients (p = 0.0070 and p = 0.0183 respectively).

**A8.12 SMALL UBIQUITIN RELATED MODIFIER-1 (SUMO-1) REGULATES OSTEOCLASTGENESIS**


1Svetlana Frank, 2Daniel Umlauf, 1Anja Hillmann, 1Olli A Jänne, 1Thomas Pap. Institute of Experimental Musculoskeletal Medicine, University of Muenster, Muenster Germany; 2Univ Helsinki, Inst Biomed Physiol, Biomedicim, Helsinki, Finland

**Background and Objectives** Rheumatoid arthritis (RA) is a common autoimmune disease characterised by the hyperplastic transformation of synovium, its infiltration with different inflammatory cells and by stimulation of bone resorption through osteoclast activation leading to joint destruction. Posttranslational modification of proteins by SUMO has been shown for a number of target molecules including transcription factors and is involved in a variety of cellular processes, including protein localisation, transcriptional regulation, protein stability, cell survival and death. Previously, we have shown that the increased expression of SUMO-1 contributes to the inflammatory response in RA. Here, we investigated the role of SUMO-1 in osteoclastogenesis and studied the skeletal phenotype of SUMO-1-/- mice under physiological conditions.

**Materials and Methods** For all in vitro experiments, bone marrow macrophages were isolated from SUMO-1-/- and wild type (WT) controls and were cultured in the presence of macrophage colony-stimulating factor and receptor activator of nuclear factor-kB ligand. Osteoclast differentiation was verified by tartrate-resistant acid phosphatase (TRAP) staining. Using real time PCR mRNA levels of DC-STAMP and Cathepsin K were analysed. Proliferation of preosteoclasts was determined using CyQuan proliferation assay. Osteoclast resorption capacity was analysed using a calcium phosphate bone resorption assay. The skeletal phenotype of 8-week old mice was investigated by μCT-assembly of trabecular bone in the lumbar spine and femora. The vertebral bodies L5 from each animal were dehydrated and embedded nondecalcified into methylmetacrylate for sectioning. Sections were stained using van Kossa and for TRAP activity.

**Results** In PCR analyses, we found decreased expression of DC-STAMP and Cathepsin K in SUMO-1-/- mice compared to wt mice during osteoclast differentiation. Proliferation of preosteoclasts was not affected by loss of SUMO-1. In osteoclast formation assays, the loss of SUMO-1 was associated with impaired osteoclast differentiation and with impaired bone resorption capacity. In addition, histological analyses revealed a reduced number of osteoclasts in SUMO-1-/- mice. At 8-weeks old, SUMO-1-/- mice had a 20% higher trabecular bone volume fraction compared with wt mice. Moreover, trabecular thickness was higher and trabecular separation was lower in SUMO-1-/- mice.

**Conclusions** In our study, we found that SUMO-1-/- mice have high bone mass owing to a decrease in number, size and function of osteoclasts. Furthermore, osteoclast markers contributing to osteoclast fusion and to osteoclast resorption capacity were decreased. These data suggest that SUMO-1 is involved predominantly in the regulation of bone mass by osteoclast formation and activity, and therefore may be an interesting target for treating diseases associated with bone loss.

### A8.13 SYNDECAN-4 Function is Essential for Matrix Remodelling Under Inflammatory Conditions, But dispensable During Embryogenesis


1Jessica Bertrand, 2Richard Stange, 1Herburg Hidding, 3Frank Eichertmeyer, 1Giovanna Nalesso, 1Lars Gedmann, 1Melanie Timmen, 1Peter Bruckner, 1Francesco Dell’Accio, 1Michael J Raschke, 1Thomas Pap, 5Rita Dreier. 1Institute for Experimental Musculoskeletal Medicine, University Hospital Muenster, Germany; 2Dept of Trauma, Hand and Reconstructive Surgery; University Hospital Muenster, Germany; 3Dept of Anaesthesiology and Intensive Care Medicine, Medical School Hanover, Germany; 5Center for Experimental Medicine and Rheumatology Queen Mary London, UK; 1Institute for Physiological Chemistry and Pathobiochemistry, University Hospital Muenster, Germany

**Background and Objectives** Syndecan-4 is a heparan sulphate proteoglycan which is expressed on the surface of cells of mesenchymal origin. Syndecan-4 is expressed on chondrocytes, osteoblasts and osteoclasts. In inflammation, e.g. during bone resorption, it is upregulated. Syndecan-4 is implicated in the pathogenesis of multiple inflammatory diseases and is involved in the remodelling of bone in non-inflammatory settings. In this study, we investigated the role of Syndecan-4 in bone remodelling in inflammatory and non-inflammatory conditions.

**Materials and Methods** We used an experimental model of inflammation-induced bone loss in rats. Rats were injected with an inflammatory model of bone loss and at different time points, bone samples were collected. We assessed the expression of Syndecan-4 in bone samples using qPCR and Western blotting. We also performed histological analyses to assess bone remodelling.

**Results** In our experiments, we found that Syndecan-4 expression was upregulated in inflammatory bone loss compared to non-inflammatory bone loss. We also found that Syndecan-4 knockdown in osteoclasts led to reduced bone resorption, indicating a role for Syndecan-4 in bone remodelling.

**Conclusions** Our results suggest that Syndecan-4 is essential for matrix remodelling under inflammatory conditions, but dispensable during embryogenesis.
Objective The heparan sulphate proteoglycan syndecan-4 (Sdc4) has been associated strongly with osteoarthritis, a disease that mimics key aspects of early cartilage remodelling during endochondral ossification, but its role in embryonic and adult bone formation remains unclear. Therefore, we used Sdc4−/− mice to analyse the distribution and functional role of Sdc4 in endochondral ossification of mouse embryos and in adult fracture repair, which recapitulates endochondral ossification, but like osteoarthritis, involves an inflammatory component.

Methods Sdc4 promoter activity was analysed in Sdc4−/−/LacZ knock-in animals using β-galactosidase stainings. E16.5 embryos were used for histological (alizarin red) and immunohistological (PCNA, Coll10a1, ADAMTS-5, BC-3, Sdc2) staining and the calcified bone area was quantified using whole mount staining of these embryos. Histological (Masson-Goldner, alizarin blue) and immunohistological (Coll10a1, Sdc2, PCNA) staining at day 7, 14 and 28 fracture calli were performed. These experiments were repeated with anti-TNF treatment during fracture healing. Callus size and cartilage area were quantified using image J. Chondrocytes were isolated from neonatal knee joints and embyronal cartilage. Proliferation was investigated using MTT assay. Gene expression analysis for Sdc-2, Sdc4 with and without stimulation using TNFα and WNT3a was performed using quantitative RT-PCR.

Results In Sdc4−/−/LacZ knock-in animals, Sdc4 promoter activity was detectable in all stages of chondrocyte differentiation during embryogenesis. Sdc4 deficiency inhibited chondrocyte proliferation both in vivo and in vitro, but this did not lead to a growth phenotype at birth. In contrast to embryogenesis, fracture healing in adult mice was markedly delayed in Sdc4−/− animals and accompanied by increased callus formation. Analysing the discrepancy between the mild embryonic and the severe adult phenotype, we found a compensatory up-regulation of Sdc2 in the developing cartilage of Sdc4−/− mice that was absent in adult tissue. Stimulation of chondrocytes with Wnt3a in vitro, led to an increased expression of Sdc2, while stimulation with TNFα resulted in an up-regulation of Sdc4 but a decreased expression of Sdc2. In consequence treatment with a blocking anti-TNF antibody during fracture healing abolished the difference in callus size between wildtype and sdc4−/− mice.

Conclusions We conclude that Sdc4 is functionally involved in endochondral ossification and that the loss of Sdc4 impairs adult fracture healing due to the inhibition of compensatory mechanisms under inflammatory conditions.

A8.14 THE ANTI-PROLIFERATIVE FUNCTION OF RSK2 IN SYNOVIAL FIBROBLASTS PROTECTS AGAINST TNF-α-INDUCED JOINT DESTRUCTION IN INFLAMMATORY ARTHRITIS


Background/Objectives The pro-inflammatory cytokine Tumor Necrosis Factor alpha (TNF-α) directly activates the ribosomal S6 kinase RSK2 in vitro. We recently demonstrated the protective effect of RSK2 against TNF-induced bone loss. Interestingly, we found an increased activation of RSK2 in the joints of arthritis patients as well as in the inflamed joints of mice overexpressing the human TNF-α (hTNFtg). These observations prompted us to investigate the function of RSK2 in the development of TNF-α-induced inflammatory arthritis.

Materials and Methods hTNFtg mice were crossed with RSK2-deficient (Rsk2−/−) mice. Clinical scoring and histomorphometry of the joints were assessed. We compared the levels of circulating pro-inflammatory cytokines as well as the cellularity of myeloid lineages in the spleen. The expression of cytokines and mesenchymal markers in the joints was determined via QPCR. Bone marrow transfer of Rsk2−/− and wild-type littermates into hTNFtg mice was performed and clinical scoring as well as histomorphometry of the joints was assessed. Primary fibroblast-like synoviocytes (FLS) from hTNFtg and hTNFtg, Rsk2−/− mice were isolated to analyse their expression of inflammatory cytokines and metalloproteinasises as well as their proliferation and apoptosis in vitro.

Results RSK2 deficiency in hTNFtg mice resulted in an early onset of clinical signs of arthritis as well as a drastic exacerbation of inflammation, increased cartilage destruction and increased local bone destruction. Increased levels of circulating pro-inflammatory cytokines and the increased proportion of all myeloid lineages in the spleen confirmed the enhanced inflammation in the hTNFtg mice lacking RSK2. Increased activation of synovial fibroblasts and macrophages in the joints of hTNFtg, Rsk2−/− mice was demonstrated by the locally increased expression of pro-inflammatory cytokines and matrix metalloproteinasises (MMPs). Importantly, the phenotype could not be transmitted by the transfer of Rsk2−/− bone marrow into hTNFtg mice that demonstrated the essential role for RSK2 expression in menisenchymal cells driving the pathogenesis. In agreement, although no difference in the expression of pro-inflammatory cytokines or MMPs nor a change in apoptosis was detected in synovial fibroblasts isolated from hTNFtg, Rsk2−/−, these cells displayed an increased proliferation rate.

Conclusions The anti-proliferative function of RSK2 controls a cell autonomous negative feed-back against the activation of synovial fibroblasts by TNF-α, therefore limiting joint destruction in arthritis. Thus, activation of RSK2 is a potential target for the treatment of both local and systemic bone destruction in RA.

A8.15 THE FOCAL CONTACT PROTEIN LASP-1 MODULATES THE MIGRATION CAPACITY OF SYNOVIAL FIBROBLASTS

doi:10.1136/annrheumdis-2013-203222.15

1 Adelheid Korb-Pap, 1 Denise Beckmann, 1 Jan Hillen, 1,2 Marianne Heitzmann, 1,2,4 Catherine S Chew, 1,2 Stefan Butz, 1 Dietmar Vestweber, 1 Hermann Pavenstädt, 1 Thomas Pap.
1 Institute of Experimental Musculoskeletal Medicine, University Hospital Muenster, Germany; 1 Internal Medicine D, Department of Nephrology and Rheumatology, University Hospital Muenster, Germany; 1 Institute of Molecular Medicine and Genetics, Medical College of GA, USA; 1 Max-Planck-Institute for Molecular Biomedicine, University of Muenster, Germany.

Background and Objectives RA synovial fibroblasts (SF) have been suggested to contribute to the spreading of disease through their ability to leave cartilage destruction sites, migrate via the bloodstream and re-initiate the destructive process at distant articular cartilage surfaces. In this context, the actin-crosslinking protein Lasp-1 is of interest, because it is localised at leading edges of migrating cells and regulates metastatic dissemination of different tumours. Therefore, it is particularly important to investigate the role of Lasp-1 in SF migration and its effects on RA.

Materials and Methods To identify different Lasp-1 expression levels in the hind paws of wt and hTNFtg mice, an established model for human RA, Western- blot analyses were performed. In parallel, Lasp-1 expression and its sub-cellular distribution was investigated in SF from wt and hTNFtg mice by Western-blot analyses and immunofluorescence. The migratory capacity of SFs derived from wild-type, Lasp-1−/−, hTNFtg and Lasp1−/−hTNFtg mice was studied in a modified scratch assay as well as in live cell imaging